Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Abstract SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog. Efficacy is only moderate, and improved treatment strateg...

詳細記述

書誌詳細

出版年:	Scientific Reports
主要な著者:	Xammy Huu Wrynla, Eddie Wehri, Erik Van Dis, Scott B. Biering, Livia H. Yamashiro, Chi Zhu, Julien Stroumza, Claire Dugast-Darzacq, Thomas G. W. Graham, Xuanting Wang, Steffen Jockusch, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw J. Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, James J. Russo, Jingyue Ju, Anders M. Näär, Sarah Stanley, Julia Schaletzky
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2022-11-01
オンライン･アクセス:	https://doi.org/10.1038/s41598-022-21034-5